Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of FTX-1821 in healthy adults and patients with facioscapulohumeral muscular dystrophy
NL-OMON48094Phase 1Completed
- Sponsor
- Fulcrum Therapeutics
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) (7 arms), sponsored by Fulcrum Therapeutics. Primary endpoints: Safety and tolerability after single dose in healthy subjects and Safety and tolerability after multiple dosing in FSHD patients. Started Jan 2019; status: completed.
02
Drugs
losmapimod
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NL-OMON48094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48094.